57 research outputs found
Abstract A58: Breast cancer risk estimates from the CARE and GAIL models among black women: Howard University Cancer Center experience
No full textAddressing the Soy and Breast Cancer Relationship: Review, Commentary, and Workshop Proceedings
No full textGaining control over breast cancer risk: Transforming vulnerability, uncertainty, and the future through clinical trial participation - a qualitative study
No full textAbstract 859: Race-based survival and prognosis among lower SES women with ER/PR negative breast cancer
No full textAbstract
Background: Heterogeneity exists in survival and prognosis among women of different race with ER/PR negative (-) breast cancer. Minority women often have lower SES, which may be a confounding factor. We evaluated survival and prognosis in a cohort of lower SES non-Hispanic White (NHW), African-American (AA), and Hispanic (HIS) women, in an attempt to disaggregate the effects of race and SES in ER/PR- breast cancer.
Methods: Chi-square test was used to examine relationship significance [odds ratios (OR), 95% confidence intervals (CIs)]; survival function estimates were generated using Kaplan-Meier (KM) method and compared using log-rank test; proportional hazards regression models [hazard ratios (HR), 95% CIs] were used to select and evaluate factors prognostic for all-cause mortality, in 213 consecutive [30 NHW, 135 AA & 48 HIS] women treated at an urban hospital [44 months median follow-up] with ER/PR- disease.
Results: HIS women were younger than NHW [OR, 0.36; 95% CI, 0.14-0.94; p =0.0368] and AA [OR, 0.50; 95% CI, 0.26-0.96; p =0386]. Compared to NHW and HIS, AA women had more comorbid disease [ORs: 3.53; 95% CI, 1.43-8.66; p =0.0053; & 2.12; 95% CI, 1.04-4.33; p =0.0392], and worse poverty status level (PL) [ORs: 5.43; 95% CI, 2.17-13.69; p =0.0001; & 2.79; 95% CI 1.17-6.65; p =0.0192]. No significant differences were noted between groups for stage at diagnosis, grade, p53 or HER2 status, and chemotherapy use. Baseline prognostic factors were: age [HR, 0.99/yr; 95% CI, 0.98-1.02; p =0.822]; stage [(II-IV/I) HR, 2.45; 95% CI, 1.85-3.24; p <0.001]; grade [(high/low) HR, 1.19; 95% CI, 0.65-2.15; p =0.575]; p53 [(+/-) HR, 1.01; 95% CI, 0.62-1.63; p =0.982]; HER2 [(+/-) HR, 0.84; 95% CI, 0.50-1.42; p =0.521]; BMI [HR, 0.99/unit; 95% CI, 0.95-1.03; p =0.714]; comorbidity [(+/-) HR, 1.23; 95% CI, 0.76-1.98; p =0.411]; PL [(>/≤ census mean) HR, 2.43; 95% CI, 1.12-5.28; p =0.025]; and chemotherapy [(+/-) HR, 0.51; 95% CI, 0.29-0.89; p =0.017]. Race was not associated with greater hazard mortality [(Other/AA) HR, 0.83; 95% CI, 0.60-1.14; p =0.255], and unadjusted 5-yr survival for NHW, AA and HIS women was 60.9%, 52.4%, and 64.4%. 5-yr survival by race was also not different for women aged <50 yrs (p =0.3287) or ≥50 yrs (p =0.6217). Multivariable models indicated that only stage [HR, 2.45; 95% CI, 1.61-3.74; p <0.001] and chemotherapy [HR, 0.31; 95% CI, 0.10-0.95; p =0.041] remained significant prognostic factors when considered together with the other above-mentioned factors. Further, models for Triple Negative [i.e. ER-, PR-, & HER2- (TN)] phenotype (without HER2 covariate) showed similar results: stage [HR, 2.32; 95% CI, 1.45-3.70; p <0.001]; chemotherapy [HR, 0.23; 95% CI, 0.07-0.75; p =0.015].
Conclusion: Survival is not significantly different among lower SES women with ER/PR- breast cancer of different race. Stage and chemotherapy use, but not race, remained independent prognostic factors in Cox models for ER/PR- and TN disease.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 859.</jats:p
Chemoprevention for breast cancer.
No full textDespite the progress that has been made in breast cancer diagnosis and treatment, this disease is still a major health problem, being the most frequently diagnosed cancer and the first leading cause of cancer death among women both in developed and economically developing countries. In some developed countries incidence rate start to decrease from the end of last millennium and this can be explained, at least in part, by the decrease in hormone replacement therapy use by post-menopausal women. Chemoprevention has the potential to be an approach of utmost importance to reduce cancer burden at least among high-risk populations. Tamoxifen and raloxifene are both indicated for the prevention of breast cancer in women at high risk for the development of the disease, although raloxifene may have a more favorable adverse-effect profile, causing fewer uterine cancers and thromboembolic events. Aromatase inhibitors will most probably become an additional prevention treatment option in the near future, in view of the promising results observed in adjuvant trials and the interesting results of the very recently published first chemoprevention trial using an aromatase inhibitor.(2) Despite impressive results in most clinical trials performed to date, chemoprevention is still not widely used. Urgently needed are better molecular risk models to accurately identify high-risk subjects, new agents with a better risk/benefit ratio and validated biomarkers.Journal ArticleReviewSCOPUS: re.jinfo:eu-repo/semantics/publishe
- …
